Ten COVID-19 vaccines seen by mid-year, head of global pharma group says

By Stephanie Nebehay GENEVA (Reuters) - Ten COVID-19 vaccines could be available by the middle of next year if they win regulatory approval, but their inventors need patent protection, the head of the global pharmaceutical industry group said on Friday. Vaccines by Pfizer and BioNtech, as well as Moderna and AstraZeneca have shown promising results in large clinical trials, but there is no question of 'cutting corners', said Thomas Cueni, director-general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). 'So far 3 we have 3 out of 3 were hits.

Reuters November 28, 2020 00:11:41 IST
Ten COVID-19 vaccines seen by mid-year, head of global pharma group says

COVID-19 vaccines seen by mid-year, head of global pharma group says" src="https://images.firstpost.com/wp-content/uploads/reuters/11-2020/28/2020-11-27T164014Z_2_LYNXMPEGAQ0XP_RTROPTP_2_HEALTH-CORONAVIRUS-GERMANY-VACCINE.jpg" alt="Ten COVID19 vaccines seen by midyear head of global pharma group says" width="300" height="225" />

By Stephanie Nebehay

GENEVA (Reuters) - Ten COVID-19 vaccines could be available by the middle of next year if they win regulatory approval, but their inventors need patent protection, the head of the global pharmaceutical industry group said on Friday.

Vaccines by Pfizer and BioNtech, as well as Moderna and AstraZeneca have shown promising results in large clinical trials, but there is no question of "cutting corners", said Thomas Cueni, director-general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

"So far 3 we have 3 out of 3 were hits. I would expect that we will see something similar with Johnson & Johnson, I would expect that we would see similar positive results with Novavax, and many others, Sanofi Pasteur, GSK are in there, Merck," he said.

'Big Pharma' and biotech firms have invested heavily in research and development and in boosting manufacturing during the pandemic to be able to roll out vaccine doses, Cueni told a Geneva news briefing.

It would be a mistake to lift patent protection to allow compulsory licensing and try to make vaccines requiring such complex quality assurance without expert staff and quality control procedures, he said.

"We will hopefully by the next summer have probably 10 vaccines which have proven their value. But all of them really need to be submitted by rigorous scientific scrutiny by the regulators."

At the World Trade Organization (WTO), India and South Africa have proposed allowing a temporary waiver to allow compulsory licensing for patented products during the pandemic. The United States, European Union and Switzerland and others have rejected it, trade officials say.

Cueni, asked about the proposal, said: "For me this questioning of IP is really primarily politics, but it's politics which is not helpful because it would send very negative signals in terms of disrespect to the system which allowed the world to react so fast and so responsibly."

Vaccine manufacturing plants often need 50 quality assurance staff making hundreds of checks during production, he said, emphasising that the companies would not exploit the pandemic.

Cueni said that IFPMA archives showed there had never been a compulsory license granted for a vaccine and pointed to the difficult technology and know-how. Nearly every member company had committed to "not-for-profit" or socially responsible pricing during the pandemic, he added.

(Reporting by Stephanie Nebehay and Philippa Fletcher)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Elon Musk leaves behind Amazon's Bezos to become world's richest person - Bloomberg News
Business

Elon Musk leaves behind Amazon's Bezos to become world's richest person - Bloomberg News

(Reuters) -Tesla Inc chief and billionaire entrepreneur Elon Musk surpassed Amazon.com Inc's top boss Jeff Bezos to become the world's richest man, Bloomberg News reported on Thursday.

Daimler starting year with optimism after strong finish to 2020 - CEO
Business

Daimler starting year with optimism after strong finish to 2020 - CEO

FRANKFURT (Reuters) - Daimler is starting the year with optimism after a strong finish to 2020, Chief Executive Ola Kaellenius said on Thursday, adding that sales in the fourth quarter had continued the strong trend seen in the preceding three months.

Oil hits 11-month highs on Saudi cuts, shrugs off U.S. unrest
Business

Oil hits 11-month highs on Saudi cuts, shrugs off U.S. unrest

By Laura Sanicola NEW YORK (Reuters) -Oil prices edged higher on Thursday, hitting 11-month peaks as markets remained focused on Saudi Arabia's unexpected pledge to deepen its oil cuts and firmer equities, shrugging off political unrest in the United States. Brent crude rose 18 cents to $54.48 a barrel by 1:32 p.m. EST (1832 GMT) after touching $54.90, a high not seen since before the first COVID-19 lockdowns in the West.